Changes

'''Reverted to version without medical contributor'''

The '''Hepatitis B vaccine''', which is required by most states of children in order to be admitted to public school, reportedly increases the risk of multiple sclerosis. Hepatitis B is not contagious in the school setting and is not required of school teachers.  It is required of schoolchildren as a result of lobbying by its manufacturer, which makes a profit on every additional shot given.  It is extremely lucrative for a company to pass a law that requires people to buy its product.

==Recombinant hepatitis B vaccine and the risk of multiple sclerosis==

 

'''Recombinant hepatitis B vaccine and the risk of multiple sclerosis'''

<br>A prospective study<ref>http://www.neurology.org/cgi/content/abstract/63/5/838</ref>

<br>A prospective study<ref>http://www.neurology.org/cgi/content/abstract/63/5/838</ref>

From the Department of Epidemiology (Dr. Hernán), Harvard School of Public Health, Boston; Boston Collaborative Drug Surveillance Program (Drs. Susan S. Jick and Hershel Jick), Boston University, Lexington, MA; and Department of Neurology (Dr. Olek), College of Medicine, University of California, Irvine.

From the Department of Epidemiology (Dr. Hernán), Harvard School of Public Health, Boston; Boston Collaborative Drug Surveillance Program (Drs. Susan S. Jick and Hershel Jick), Boston University, Lexington, MA; and Department of Neurology (Dr. Olek), College of Medicine, University of California, Irvine.

Background: A potential link between the recombinant hepatitis B vaccine and an increased risk of multiple sclerosis (MS) has been evaluated in several studies, but some of them have substantial methodologic limitations.

===Background===

 

A potential link between the recombinant hepatitis B vaccine and an increased risk of multiple sclerosis (MS) has been evaluated in several studies, but some of them have substantial methodologic limitations.

 

 

The authors conducted a nested case-control study within the General Practice Research Database (GPRD) in the United Kingdom.

Results: The analyses include 163 cases of MS and 1,604 controls. The OR of MS for vaccination within 3 years before the index date compared to no vaccination was 3.1 (95% CI 1.5, 6.3). No increased risk of MS was associated with tetanus and influenza vaccinations.

The analysis included 163 cases of MS and 1,604 controls. The OR of MS for vaccination within 3 years before the index date compared to no vaccination was 3.1 (95% CI 1.5, 6.3). No increased risk of MS was associated with tetanus and influenza vaccinations.

Conclusions: These findings are consistent with the hypothesis that immunization with the recombinant hepatitis B vaccine is associated with an increased risk of MS, and challenge the idea that the relation between hepatitis B vaccination and risk of MS is well understood.

===Conclusions===

'''References:'''  <references/>

==References==

<references/>

[[Category:Vaccines]]

[[Category:Vaccines]]